Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

Study finds way to boost corneal transplant acceptance rate

For the estimated 10 percent of patients whose bodies reject a corneal transplant, the odds of a second transplant succeeding are poor. All that could change, however, based on a UT Southwestern Medical Center study that has found a way to boost the corneal transplant acceptance rate.

31 Dec 2013

Genzyme gets FDA Complete Response Letter for Lemtrada sBLA

Genzyme, a Sanofi company, announced today that it has received a Complete Response Letter from the U.S. Food and Drug Administration for its supplemental Biologics License Application seeking approval of Lemtrada (alemtuzumab) for the treatment of relapsing forms of multiple sclerosis.

30 Dec 2013

Cancer immunotherapy named 2013 Breakthrough of the Year by journal Science

Detect. Destroy. Remember. The mantra of the immune system's relentless campaign against infectious invaders and the body's own abnormal cells finally is applying to cancer in meaningful ways.

28 Dec 2013

Study suggests that cocktail of AMA1 proteins can overcome major limitations of AMA1-based vaccines

A safe and effective malaria vaccine is high on the wish list of most people concerned with global health. Results published on December 26 in PLOS Pathogens suggest how a leading vaccine candidate could be vastly improved.

27 Dec 2013

FDA extends PDUFA Priority Review action date for UC indication of Takeda's vedolizumab

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., today announced that the United States Food & Drug Administration has extended the Prescription Drug User Fee Act Priority Review action date for the ulcerative colitis indication of Takeda's investigational biologic, vedolizumab.

24 Dec 2013

Paired exchange and incompatible kidney transplant program launched by UAB

Ann Marie Reynolds, a 32-year-old who has been in and out of hospitals fighting chronic kidney disease since she was a teenager, had a less than 1 percent chance of receiving a kidney without the University of Alabama at Birmingham's groundbreaking organ donation system that helped her and two other hard-to-match patients get kidneys in a three-way, incompatible kidney exchange earlier this year.

24 Dec 2013

Study finds link between genes affected by testosterone and antibody responses to influenza vaccine

A new study has identified a link between certain genes affected by testosterone and antibody responses to an influenza vaccine. The findings, published in Proceedings of the National Academy of Sciences, suggest that testosterone levels may partially explain why men often have weaker responses to vaccines than women.

24 Dec 2013

Research findings reveal how immune system responds to respiratory viral infections

An antibody that blocks a component of a key signaling pathway in the respiratory airways could help the immune system rid the body of the influenza virus, a new study suggests. The findings, from a team at The Research Institute at Nationwide Children's Hospital, not only offer a new approach to treating the flu, but also add new information about how the immune system responds to respiratory viral infections.

24 Dec 2013

Reflux disease diagnosis: an interview with Professor Peter Dettmar, Managing Director of RD Biomed Limited

Generally speaking, reflux has been a major chronic issue for probably the last 40 or 50 years. When you look at the global population, depending on which country we're talking about, around 20% to 40% of individuals have reflux disease within their populations.

23 Dec 2013

European Commission approves update of Erbitux to treat patients with RAS wild-type mCRC

Merck Serono, the biopharmaceutical division of Merck, today announced that the European Commission has approved the Type II variation to amend the Erbitux(cetuximab) product information, updating the indication for Erbitux to the treatment of patients with RAS wild-type metastatic colorectal cancer (mCRC).

23 Dec 2013

Researchers develop possible new method for treating pancreatic cancer

A possible new method for treating pancreatic cancer which enables the body's immune system to attack and kill cancer cells has been developed by researchers.

22 Dec 2013

New antibody could boost strength, muscle mass in patients with cancer and other diseases

A new antibody could dramatically boost strength and muscle mass in patients with cancer, chronic obstructive pulmonary disease, sporadic inclusion body myositis, and in elderly patients with sarcopenia according to research published ahead of print in the journal Molecular and Cellular Biology.

20 Dec 2013

Amgen reports that Phase 3 DESCARTES study for high cholesterol meets primary endpoint

Amgen today announced that the Phase 3 DESCARTES (Durable Effect of PCSK9 Antibody CompARed wiTh PlacEbo Study) study evaluating the long-term 52-week safety and efficacy of evolocumab for the treatment of high cholesterol met its primary endpoint of percent reduction from baseline in low-density lipoprotein cholesterol (LDL-C) at week 52.

20 Dec 2013

FibroGen starts patient enrollment in FG-3019 Phase 2 study for idiopathic pulmonary fibrosis treatment

FibroGen, Inc., announced today that patient enrollment has started in a new Phase 2 clinical study of FG-3019 in patients who suffer from idiopathic pulmonary fibrosis.

20 Dec 2013

Takeda to acquire exclusive license to develop Natrogen's Natura-alpha compound

Takeda Pharmaceutical Company Limited and Natrogen Therapeutics International, Inc. jointly announced today an agreement whereby Takeda will acquire an exclusive license to develop Natrogen's Natura-alpha compound as well as an option to acquire Natrogen. Natura-alpha is a synthetic small molecule oral compound that is believed to inhibit pro-inflammatory cytokine expression, which may help to reduce gastrointestinal inflammation. Natura-alpha is currently in Phase 2 development for the treatment of ulcerative colitis.

20 Dec 2013

FDA approves Baxter's FEIBA for prophylactic treatment of hemophilia patients with inhibitors

Baxter International Inc. today announced that the United States Food and Drug Administration granted approval of Baxter's FEIBA [Anti-Inhibitor Coagulant Complex], the first and only FDA-approved treatment for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in patients with hemophilia A or B who have developed inhibitors.

From Baxter International Inc. 20 Dec 2013

Australian Therapeutic Goods Administration approves Genzyme's Lemtrada for multiple sclerosis

Genzyme, a Sanofi company, announced today that the Australian Therapeutic Goods Administration has approved Lemtrada (alemtuzumab) for the treatment of relapsing forms of multiple sclerosis for patients with active disease defined by clinical or imaging features to slow the accumulation of physical disability and reduce the frequency of clinical relapses.

19 Dec 2013

Sorrento Therapeutics acquires Concortis Biosystems

Sorrento Therapeutics, Inc. announced today that it has completed its acquisition of Concortis Biosystems, Corp., providing Sorrento with a comprehensive technology platform to create a new generation of homogenous antibody drug conjugates with site-specific toxin conjugation and consistent drug-antibody ratios. With the close of the deal, Sorrento has issued an aggregate of 1,331,978 shares of its common stock to the Concortis shareholders. Based on the closing share price on December 18, 2013, the transaction is valued at $11.3 million.

19 Dec 2013

Randomized control trials to study clinical effectiveness of high dose flu vaccine in nursing homes

One of the highest risk groups for developing pneumonia or even dying from the flu is the elderly, especially in group settings such as nursing homes.

19 Dec 2013

Sanofi and Regeneron Pharmaceuticals team up with ACC to enhance clinical research with alirocumab

Sanofi and Regeneron Pharmaceuticals, Inc. today announced an innovative collaboration with the American College of Cardiology focused on enhancing clinical research with alirocumab, an investigational monoclonal antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9). PCSK9 is known to contribute to circulating low-density lipoprotein cholesterol (LDL-C) levels. Alirocumab is being co-developed by Sanofi and Regeneron.

19 Dec 2013

Antibody News and Research

Further Reading

Study finds way to boost corneal transplant acceptance rate

Genzyme gets FDA Complete Response Letter for Lemtrada sBLA

Cancer immunotherapy named 2013 Breakthrough of the Year by journal Science

Study suggests that cocktail of AMA1 proteins can overcome major limitations of AMA1-based vaccines

FDA extends PDUFA Priority Review action date for UC indication of Takeda's vedolizumab

Paired exchange and incompatible kidney transplant program launched by UAB

Study finds link between genes affected by testosterone and antibody responses to influenza vaccine

Research findings reveal how immune system responds to respiratory viral infections

Reflux disease diagnosis: an interview with Professor Peter Dettmar, Managing Director of RD Biomed Limited

European Commission approves update of Erbitux to treat patients with RAS wild-type mCRC

Researchers develop possible new method for treating pancreatic cancer

New antibody could boost strength, muscle mass in patients with cancer and other diseases

Amgen reports that Phase 3 DESCARTES study for high cholesterol meets primary endpoint

FibroGen starts patient enrollment in FG-3019 Phase 2 study for idiopathic pulmonary fibrosis treatment

Takeda to acquire exclusive license to develop Natrogen's Natura-alpha compound

FDA approves Baxter's FEIBA for prophylactic treatment of hemophilia patients with inhibitors

Australian Therapeutic Goods Administration approves Genzyme's Lemtrada for multiple sclerosis

Sorrento Therapeutics acquires Concortis Biosystems

Randomized control trials to study clinical effectiveness of high dose flu vaccine in nursing homes

Sanofi and Regeneron Pharmaceuticals team up with ACC to enhance clinical research with alirocumab

Using single B cell screening to boost antibody discovery eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo